

UniQuest — University of Queensland's Commercialisation Company

City Innovation Library · Good practice · Australia

Quality score: 71/100

Evidence strength: Strong

Summary

UniQuest, UQ's commercialisation company since 1984, has produced 360+ US patents and 130+ start-ups (Gardasil, Spinifex, Inflazome); in July 2025 Sanofi agreed to acquire its spin-out Vicebio for up to US\$1.6bn — Australia's largest-ever university IP deal.

Key dimensions

Dimension	Score
Evidence of impact / measured results	3/3
Transferability / demonstrated replication	1/3
Scalability	3/3
Sustainability / continuity	3/3
Innovation	2/3
Inclusiveness / equity	0/3
Multi-stakeholder collaboration	3/3

Evaluated by C-NAPSE

Data sources

[C-NAPSE web research](#) — accessed 2026-07-08

[UniQuest Pty Limited \(wholly owned by The University of Queensland\)](#) — accessed 2026-07-08

[Billion-dollar deal takes UQ vaccine tech to the world – UQ News](#) — accessed 2026-07-08

[Sanofi to acquire Vicebio – Sanofi press release](#) — accessed 2026-07-08

[Vicebio to be acquired by Sanofi for US\\$1.6 billion – PR Newswire](#) — accessed 2026-07-08

Cite this — Evidoria. *UniQuest — University of Queensland's Commercialisation Company*. Persistent ID: 78bcf0aa-854f-4cd2-8a14-63b9a4dbef33.